Esperion Therapeutics, Inc.

NasdaqGM:ESPR Stock Report

Market Cap: US$444.8m

Esperion Therapeutics Valuation

Is ESPR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • PM vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ESPR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ESPR ($2.63) is trading below our estimate of fair value ($106.24)

Significantly Below Fair Value: ESPR is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for ESPR?

Other financial metrics that can be useful for relative valuation.

ESPR key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue8.4x
Enterprise Value/EBITDA-5.5x
PEG Ration/a

Price to Sales Ratio vs Peers

How does ESPR's PS Ratio compare to its peers?

The above table shows the PS ratio for ESPR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average8.9x
TBPH Theravance Biopharma
7.9x25.9%US$436.2m
ZVRA Zevra Therapeutics
16.6x42.9%US$282.1m
SIGA SIGA Technologies
10.5x64.4%US$369.0m
PAHC Phibro Animal Health
0.5x3.2%US$507.5m
ESPR Esperion Therapeutics
4.4x38.3%US$444.8m

Price-To-Sales vs Peers: ESPR is good value based on its Price-To-Sales Ratio (4.4x) compared to the peer average (9x).


Price to Earnings Ratio vs Industry

How does ESPR's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a20.9%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a20.9%
n/an/an/a
No more companies

Price-To-Sales vs Industry: ESPR is expensive based on its Price-To-Sales Ratio (4.4x) compared to the US Pharmaceuticals industry average (3.2x).


Price to Sales Ratio vs Fair Ratio

What is ESPR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ESPR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.4x
Fair PS Ratio2.9x

PM vs Fair Ratio: ESPR is expensive based on its Price-To-Sales Ratio (4.4x) compared to the estimated Fair Price-To-Sales Ratio (2.9x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ESPR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$2.61
US$8.54
+227.3%
71.3%US$22.00US$2.80n/a7
Feb ’25US$2.07
US$8.54
+312.7%
71.3%US$22.00US$2.80n/a7
Jan ’25US$2.99
US$8.25
+175.9%
69.8%US$22.00US$2.00n/a8
Dec ’24US$1.44
US$8.25
+472.9%
69.8%US$22.00US$2.00n/a8
Nov ’24US$0.86
US$11.13
+1,195.1%
62.5%US$22.00US$2.00n/a8
Oct ’24US$0.98
US$11.13
+1,035.2%
62.5%US$22.00US$2.00n/a8
Sep ’24US$1.56
US$10.28
+558.8%
67.9%US$22.00US$2.00n/a9
Aug ’24US$1.69
US$10.28
+508.2%
67.9%US$22.00US$2.00n/a9
Jul ’24US$1.39
US$10.50
+655.4%
67.3%US$22.00US$1.00n/a9
Jun ’24US$1.33
US$10.08
+657.5%
69.7%US$22.00US$1.00n/a10
May ’24US$1.42
US$11.20
+688.7%
63.0%US$22.00US$1.00n/a10
Apr ’24US$1.59
US$10.45
+557.5%
68.2%US$22.00US$1.00n/a11
Mar ’24US$6.00
US$11.38
+89.6%
50.7%US$22.00US$3.00n/a12
Feb ’24US$6.40
US$11.00
+71.9%
55.5%US$22.00US$3.00US$2.0711
Jan ’24US$6.23
US$11.00
+76.6%
55.5%US$22.00US$3.00US$2.9911
Dec ’23US$6.94
US$11.27
+62.4%
52.7%US$22.00US$3.00US$1.4411
Nov ’23US$8.28
US$10.82
+30.7%
57.2%US$22.00US$3.00US$0.8611
Oct ’23US$6.70
US$10.27
+53.3%
61.0%US$22.00US$3.00US$0.9811
Sep ’23US$7.69
US$10.27
+33.6%
61.0%US$22.00US$3.00US$1.5611
Aug ’23US$5.45
US$10.55
+93.5%
59.9%US$22.00US$3.00US$1.6911
Jul ’23US$6.45
US$10.36
+60.7%
62.2%US$22.00US$3.00US$1.3911
Jun ’23US$5.42
US$10.36
+91.2%
62.2%US$22.00US$3.00US$1.3311
May ’23US$5.68
US$10.55
+85.7%
64.2%US$22.00US$3.50US$1.4210
Apr ’23US$4.96
US$10.55
+112.7%
64.2%US$22.00US$3.50US$1.5910
Mar ’23US$4.29
US$9.15
+113.3%
61.3%US$22.00US$3.50US$6.0010
Feb ’23US$4.43
US$10.45
+136.0%
71.0%US$27.00US$4.00US$6.4011

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.